The company previously provided an update in April 2025 stating its intention to lay off approximately 65% of the company ...

Annexin Pharmaceuticals initiates a Phase 2a study for ANXV in diabetic retinopathy to explore new treatment options and ...

Best disease, or vitelliform macular dystrophy, is a rare, inherited retinal condition causing macular degeneration by ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

The lesion characteristics of patients with geographic atrophy (GA) were found to affect the lesion growth rate, with ...

The two aim to develop a potential first-in-class melanocortin receptor-targeted treatment for patients with retinal diseases ...

Omer Trivizki discusses promising results of VOY-101, a gene therapy for geographic atrophy, highlighting safety and next ...

Cyte initiates patient dosing in a new trial for famzeretcel, aiming to transform treatment options for retinitis pigmentosa.

Extend the summer at EyeCon 2025—where clinical insight meets coastal vibes—September 26 and 27 at the Margaritaville Hollywood Beach Resort in Florida.